Zafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development
Dr. Singhal joins
“Priya is a seasoned and exceptional industry leader, and we are thrilled to welcome her to
During her tenure at Biogen, Dr. Singhal led the worldwide benefit-risk strategy for the Biogen portfolio as well as for the filings and approvals of six products, including Tecfidera and Spinraza. She also contributed to Biogen’s overall R&D strategy and drug development plans, chaired safety governance for the entire portfolio, and led numerous successful portfolio and product interactions with regulators worldwide.
“Throughout my career I have been drawn to opportunities to lead translation from new scientific insights into safe and effective treatments that make a difference for patients and their families,” said Dr. Singhal. “Zafgen is highly scientific and patient-centric in its approach. I am excited to collaborate with this dedicated team and bring my experience across the drug development life cycle to guide the R&D strategy and realize the full potential of this pathway.”
Prior to Biogen, Dr. Singhal held roles of increasing seniority at
Dr. Singhal earned her M.P.H. at
Safe Harbor Statement
Various statements in this release concerning Zafgen’s future expectations, plans and prospects, including without limitation, Zafgen’s expectations regarding the use of ZGN-1258, ZGN-1061 and other second-generation MetAP2 inhibitors as treatments for metabolic diseases including Prader-Willi syndrome, type 2 diabetes, liver diseases and obesity and Zafgen’s expectations with respect to the timing and success of its nonclinical studies and clinical trials of ZGN-1258, ZGN-1061 and its other product candidates, may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen’s ability to successfully demonstrate the efficacy and safety of ZGN-1258, ZGN-1061 and its other product candidates and to differentiate ZGN-1258, ZGN-1061 and its other product candidates from first generation MetAP2 inhibitors, such as beloranib, the nonclinical and clinical results for ZGN-1258, ZGN-1061 and its other product candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect the initiation, timing and progress of nonclinical studies and clinical trials of its product candidates, Zafgen’s ability to obtain, maintain and protect its intellectual property, Zafgen’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen’s ability to manage operating expenses, Zafgen’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives when needed, Zafgen’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Zafgen’s most recent Annual Report on Form 10-K filed with the
Media/Investor Relations Contacts:
Chief Financial Officer
Ten Bridge Communications
Westwicke, An ICR Company
Source: Zafgen, Inc.